Acute diarrhoea is a significant cause of morbidity and death in children. Racecadotril is an antisecretory medication that is used as an adjuvant antidiarrheal therapy. The enzyme neutral endopeptidase (NEP) blocks the activity of enkephalins in the small intestine, preventing water and electrolyte hypersecretion. Racecadotril inhibits NEP, allowing enkephalins to exert their antisecretory actions. As a result, racecadotril decreases water and electrolyte output in the small intestine while having no effect on intestinal motility. There have been no reports of significant adverse effects associated with racecadotril.
Racecadotril has demonstrated effectiveness as an adjuvant antidiarrheal medication with a favourable safety profile. Its use in oral rehydration solution (ORS) is therapeutically helpful and may result in health-care savings.
Reference:https://journals.lww.com/jpgn/Fulltext/2020/02000/Drugs_in_Focus__The_Use_of_Racecadotril_in.5.aspx
